Pharmaceuticals, Biotechnology and Life Sciences
Herantis Pharma has gotten positive results from a safety evaluation in the ongoing Phase 1 clinical study of its investigational…
Herantis Pharma’s clinical study with its investigational gene therapy product Lymfactin for treating secondary lymphedema has advanced to the last patient cohort, owing to good reported safety, the company said Thursday.
Herantis Pharma clinical study with the company’s innovative gene therapy investigational product Lymfactin for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety.